A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
NCT ID: NCT01877915
Last Updated: 2019-05-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
5081 participants
INTERVENTIONAL
2013-09-10
2018-04-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
NCT03455439
Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
NCT01839357
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
NCT03087487
RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
NCT02303795
An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)
NCT04970381
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rivaroxaban 2.5 mg
Each participant will receive 2.5 mg of rivaroxaban twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Rivaroxaban
Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Standard of care for heart failure and coronary artery disease
Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
Placebo
Each participant will receive matching placebo twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Placebo
Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Standard of care for heart failure and coronary artery disease
Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rivaroxaban
Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Placebo
Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Standard of care for heart failure and coronary artery disease
Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have an episode of decompensated heart failure (index event) requiring (a) an overnight stay \[that is, staying past midnight\] in a hospital, emergency department, or medical facility with the capability of treating with intravenous medications and observing heart failure patients before randomization or (b) an unscheduled outpatient visit to a heart failure management center, where parenteral therapy is required for heart failure stabilization. An episode of decompensated heart failure is defined as symptoms of worsening dyspnea or fatigue, objective signs of congestion such as peripheral edema or ascites, and/or adjustment of pre-hospitalization/outpatient visit heart failure medications. Participants are eligible for randomization at discharge from the facility treating the index event and up to 30 days after discharge if they are in stable condition
* Must have a documented left ventricular ejection fraction (LVEF) of less than or equal to 40 percent (%) within 1 year before randomization
* Must have evidence of significant coronary artery disease
* Must be medically stable in terms of their heart failure clinical status at the time of randomization
* Must have a brain natriuretic peptide (BNP) level greater than or equal to (\>=) 200 picogram per milliliter (pg/mL) or N-terminal-proBNP (NT-proBNP) level \>=800 pg/mL (preferred assay) during the Screening period and before randomization
Exclusion Criteria
* Severe concomitant disease such as (a) atrial fibrillation (AFib) or another condition that requires chronic anticoagulation (participants with isolated transient AFib may be allowed at the discretion of the treating physician investigator) and (b) Documented acute myocardial infarction (MI) during index event
* Prior stroke within 90 days of randomization
* Has been hospitalized for longer than 21 days during the index event
* Planned intermittent outpatient treatment with positive inotropic drugs administered intravenously
18 Years
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Janssen Research & Development, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen Research & Development, LLC Clinical Trial
Role: STUDY_DIRECTOR
Janssen Research & Development, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kuala Lumpur, , Malaysia
Kuala Selangor, , Malaysia
Kuching, , Malaysia
Selayang Baru Utara, , Malaysia
Aguascalientes, , Mexico
Benito Juárez, , Mexico
Chihuahua City, , Mexico
Alexander City, Alabama, United States
Birmingham, Alabama, United States
Mobile, Alabama, United States
Anchorage, Alaska, United States
Tucson, Arizona, United States
Jonesboro, Arkansas, United States
Beverly Hills, California, United States
Chula Vista, California, United States
El Cajon, California, United States
Glendale, California, United States
La Mesa, California, United States
Los Angeles, California, United States
Newport Beach, California, United States
Orange, California, United States
Stockton, California, United States
Torrance, California, United States
Aurora, Colorado, United States
Denver, Colorado, United States
New Haven, Connecticut, United States
Atlantis, Florida, United States
Daytona Beach, Florida, United States
Jupiter, Florida, United States
Orlando, Florida, United States
St. Petersburg, Florida, United States
Tallahassee, Florida, United States
Wellington, Florida, United States
Winter Haven, Florida, United States
Athens, Georgia, United States
Atlanta, Georgia, United States
Cumming, Georgia, United States
Macon, Georgia, United States
Tucker, Georgia, United States
Chicago, Illinois, United States
Evanston, Illinois, United States
Fairview Heights, Illinois, United States
Peoria, Illinois, United States
Rockford, Illinois, United States
Urbana, Illinois, United States
Anderson, Indiana, United States
Indianapolis, Indiana, United States
Merrillville, Indiana, United States
Munster, Indiana, United States
South Bend, Indiana, United States
Iowa City, Iowa, United States
Elizabethtown, Kentucky, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
Owensboro, Kentucky, United States
Bossier City, Louisiana, United States
Hammond, Louisiana, United States
Shreveport, Louisiana, United States
Slidell, Louisiana, United States
Biddeford, Maine, United States
Baltimore, Maryland, United States
Columbia, Maryland, United States
Randallstown, Maryland, United States
Bay City, Michigan, United States
Grand Blanc, Michigan, United States
Mount Clemens, Michigan, United States
Pontiac, Michigan, United States
Ypsilanti, Michigan, United States
Saint Paul, Minnesota, United States
Springfield, Missouri, United States
St Louis, Missouri, United States
Washington, Missouri, United States
Lincoln, Nebraska, United States
Las Vegas, Nevada, United States
Bridgewater, New Jersey, United States
Elmer, New Jersey, United States
Haddon Heights, New Jersey, United States
Manalapan, New Jersey, United States
Ridgewood, New Jersey, United States
Sewell, New Jersey, United States
Albuquerque, New Mexico, United States
Buffalo, New York, United States
Cortlandt Manor, New York, United States
Jamaica, New York, United States
Mineola, New York, United States
New York, New York, United States
Charlotte, North Carolina, United States
High Point, North Carolina, United States
Pinehurst, North Carolina, United States
Canton, Ohio, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Dayton, Ohio, United States
Fairfield, Ohio, United States
Kettering, Ohio, United States
Bartlesville, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
Portland, Oregon, United States
Doylestown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Sayre, Pennsylvania, United States
Sellersville, Pennsylvania, United States
Wynnewood, Pennsylvania, United States
Yardley, Pennsylvania, United States
York, Pennsylvania, United States
Charleston, South Carolina, United States
Sioux Falls, South Dakota, United States
Nashville, Tennessee, United States
Cypress, Texas, United States
Dallas, Texas, United States
Fort Worth, Texas, United States
Houston, Texas, United States
Huntsville, Texas, United States
Kingwood, Texas, United States
Lubbock, Texas, United States
McKinney, Texas, United States
Burlington, Vermont, United States
Newport News, Virginia, United States
Bellingham, Washington, United States
Tacoma, Washington, United States
Huntington, West Virginia, United States
Bahía Blanca, , Argentina
Buenos Aires, , Argentina
Caba, , Argentina
Córdoba, , Argentina
La Plata, , Argentina
Mar del Plata, , Argentina
Mendoza, , Argentina
Merlo, , Argentina
Quilmes, , Argentina
Resistencia, , Argentina
Rosario, , Argentina
San Miguel de Tucumán, , Argentina
San Nicolás, , Argentina
Santa Fe, , Argentina
Santiago del Estero, , Argentina
Vicente López, , Argentina
Bedford, , Australia
Cairns, , Australia
Concord, , Australia
Darlinghurst, , Australia
Hobart, , Australia
Launceston, , Australia
Perth, , Australia
Sydney, , Australia
Wollongong, , Australia
Woolloongabba, , Australia
Belém, , Brazil
Belo Horizonte, , Brazil
Blumenal, , Brazil
Brasília, , Brazil
Campina Grande do Sul, , Brazil
Campinas, , Brazil
Campo Grande, , Brazil
Canoas, , Brazil
Curitiba, , Brazil
Goiânia, , Brazil
Marília, , Brazil
Passo Fundo, , Brazil
Porto Alegre, , Brazil
Recife, , Brazil
Ribeirão Preto, , Brazil
Rio de Janeiro, , Brazil
Salvador, , Brazil
São Jose Do Rio Preto, , Brazil
São Paulo, , Brazil
São Pedro, , Brazil
Tatuí, , Brazil
Uberlândia, , Brazil
Votuporanga, , Brazil
Blagoevgrad, , Bulgaria
Burgas, , Bulgaria
Dimitrovgrad, , Bulgaria
Kazanlak, , Bulgaria
Pazardzhik, , Bulgaria
Pleven, , Bulgaria
Plovdiv, , Bulgaria
Rousse, , Bulgaria
Sofia, , Bulgaria
Stara Zagora, , Bulgaria
Varna, , Bulgaria
Veliko Tarnovo, , Bulgaria
Edmonton, Alberta, Canada
Maple Ridge, British Columbia, Canada
St. John's, Newfoundland and Labrador, Canada
Halifax, Nova Scotia, Canada
Cambridge, Ontario, Canada
Kitchener, Ontario, Canada
London, Ontario, Canada
Ottawa, Ontario, Canada
Scarborough Village, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Baotou, , China
Beijing, , China
Changchun, , China
Changsha, , China
Chengdu, , China
Daqing, , China
Guangzhou, , China
Haikou, , China
Hangzhou, , China
Hunan, , China
Jinan, , China
Jining, , China
Lanzhou, , China
Nanchang, , China
Nanjing, , China
Nanning, , China
Qingdao, , China
Shanghai, , China
Shenyang, , China
Shijiazhuang, , China
Suzhou, , China
Taiyuan, , China
Tianjin, , China
Wuhan, , China
Xi'an, , China
Yangzhou, , China
Yichang, , China
Brno, , Czechia
Hodonín, , Czechia
Hradec Králové, , Czechia
Hranice, , Czechia
Karlovy Vary, , Czechia
Kladno, , Czechia
Kolín, , Czechia
Litomyšl, , Czechia
Mladá Boleslav, , Czechia
Olomouc, , Czechia
Plze?-Bory, , Czechia
Prague, , Czechia
Praha 8 - Libe?, , Czechia
Slaný, , Czechia
Teplice, , Czechia
Uherské Hradišt?, , Czechia
Valašské Mezi?í?í, , Czechia
Esbjerg, , Denmark
Herlev, , Denmark
Hjørring, , Denmark
Hvidovre, , Denmark
Køge, , Denmark
Tallinn, , Estonia
Besançon, , France
Bron, , France
Chambray-lès-Tours, , France
Corbeil-Essonnes, , France
Lille, , France
Montpellier, , France
Nantes, , France
Nice, , France
Pau, , France
Rouen, , France
Toulouse, , France
Vandœuvre-lès-Nancy, , France
Berlin, , Germany
Bielefeld, , Germany
Bonn, , Germany
Coburg, , Germany
Dresden, , Germany
Halle, , Germany
Hamburg, , Germany
Heidelberg, , Germany
Konstanz, , Germany
Langen, , Germany
Leipzig, , Germany
Ludwigshafen, , Germany
Magdeburg, , Germany
Mainz, , Germany
Markkleeberg, , Germany
Papenburg, , Germany
Stuttgart, , Germany
Ulm, , Germany
Witten, , Germany
Athens, , Greece
Heraklion -Crete, , Greece
Larissa, , Greece
Thessalonikis, , Greece
Voula, , Greece
Balatonfüred, , Hungary
Berettyóújfalu, , Hungary
Budapest, , Hungary
Győr, , Hungary
Miskolc, , Hungary
Nagykanizsa, , Hungary
Szekszárd, , Hungary
Székesfehérvár, , Hungary
Szolnok, , Hungary
Zalaegerszeg, , Hungary
Aichi, , Japan
Chiba, , Japan
Chikushino-shi, , Japan
Ehime, , Japan
Fukuoka, , Japan
Gifu, , Japan
Gunma, , Japan
Hatsukaichi, , Japan
Hitachi, , Japan
Hokkaido, , Japan
Hyōgo, , Japan
Ibaraki, , Japan
Ishikawa, , Japan
Izumo, , Japan
Kagawa, , Japan
Kahoku-District, , Japan
Kanagawa, , Japan
Kobe, , Japan
Komatsushima-shi, , Japan
Koshigaya-shi, , Japan
Kumamoto, , Japan
Kyoto, , Japan
Miyazaki, , Japan
Nagano, , Japan
Nagasaki, , Japan
Nagoya, , Japan
Niigata, , Japan
Okayama, , Japan
Okinawa, , Japan
Osaka, , Japan
Ōita, , Japan
Saga, , Japan
Saitama, , Japan
Sapporo, , Japan
Sendai, , Japan
Shiga, , Japan
Shimane, , Japan
Shizuoka, , Japan
Tachikawa, , Japan
Takaraduka, , Japan
Tochigi, , Japan
Tokushima, , Japan
Tokyo, , Japan
Toyama, , Japan
Toyoake, , Japan
Tsu, , Japan
Wakayama, , Japan
Yamaguchi, , Japan
Yatsushiro, , Japan
Yokohama, , Japan
Yonago, , Japan
Daugavpils, , Latvia
Kuldīga, , Latvia
Liepāja, , Latvia
Riga, , Latvia
Sigulda, , Latvia
Ventspils, , Latvia
Alytus, , Lithuania
Kaunas, , Lithuania
Klaipėda, , Lithuania
Panevezys, , Lithuania
Šiauliai, , Lithuania
Vilnius, , Lithuania
Cheras, , Malaysia
George Town, , Malaysia
Johor Bahru, , Malaysia
Kota Kinabalu, , Malaysia
Culiacán, , Mexico
Durango, , Mexico
Guadalajara, , Mexico
León, , Mexico
Mexico City, , Mexico
México, , Mexico
Oaxaca City, , Mexico
Pachuca, , Mexico
Puebla City, , Mexico
Querétaro, , Mexico
San Luis Potosí City, , Mexico
Tampico, , Mexico
Veracruz, , Mexico
Almere Stad, , Netherlands
Amsterdam, , Netherlands
Blaricum, , Netherlands
Breda, , Netherlands
Deventer, , Netherlands
Doetinchem, , Netherlands
Ede, , Netherlands
Groningen, , Netherlands
Heerlen, , Netherlands
Helmond, , Netherlands
Maastricht, , Netherlands
Meppel, , Netherlands
Tilburg, , Netherlands
Będzin, , Poland
Gdynia, , Poland
Gliwice, , Poland
Grodzisk Mazowiecki, , Poland
Inowrocław, , Poland
Katowice, , Poland
Kielce, , Poland
Krakow, , Poland
Kutno, , Poland
Lodz, , Poland
Lubin, , Poland
Lublin, , Poland
Myślenice, , Poland
Olsztyn, , Poland
Ostrowiec Świętokrzyski, , Poland
Ostrołęka, , Poland
Oświęcim, , Poland
Puławy, , Poland
Płock, , Poland
Rabka-Zdrój, , Poland
Skierniewice, , Poland
Starogard Gdański, , Poland
Szczecin, , Poland
Torun, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Włocławek, , Poland
Zabrze, , Poland
Zamość, , Poland
Łódż, , Poland
Almada, , Portugal
Aveiro, , Portugal
Braga, , Portugal
Carnaxide, , Portugal
Coimbra, , Portugal
Covilha, , Portugal
Leiria, , Portugal
Lisbon, , Portugal
Matosinhos Municipality, , Portugal
Viana do Castelo, , Portugal
Vila Real, , Portugal
Bacau, , Romania
Baia Mare, , Romania
Brasov, , Romania
Brăila, , Romania
Bucharest, , Romania
Buzău, , Romania
Cluj-Napoca, , Romania
Craiova, , Romania
Focşani, , Romania
Galati, , Romania
Iași, , Romania
Oradea, , Romania
Piteşti, , Romania
Sibiu, , Romania
Târgu Mureş, , Romania
Timișoara, , Romania
Arkhangelsk, , Russia
Barnaul, , Russia
Chita, , Russia
Ivanovo, , Russia
Izhevsk, , Russia
Kaluga, , Russia
Kemerovo, , Russia
Kirov, , Russia
Krasnoyarsk, , Russia
Kursk, , Russia
Moscow, , Russia
Moscow, Zelenograd, , Russia
Nizhny Novgorod, , Russia
Novosibirsk, , Russia
Orenburg, , Russia
Perm, , Russia
Rostov-on-Don, , Russia
Ryazan, , Russia
Saint Petersburg, , Russia
Samara, , Russia
Saratov, , Russia
Syktyvkar, , Russia
Tomsk, , Russia
Tyumen, , Russia
Voronezh, , Russia
Yaroslavl, , Russia
Yekaterinburg, , Russia
Banská Bystrica, , Slovakia
Bardejov, , Slovakia
Košice, , Slovakia
Lučenec, , Slovakia
Moldava nad Bodvou, , Slovakia
Nitra, , Slovakia
Považská Bystrica, , Slovakia
Svidník, , Slovakia
Bloemfontein, , South Africa
Cape Town, , South Africa
Centurion, , South Africa
Durban, , South Africa
Pinelands, , South Africa
Pretoria, , South Africa
Tongaat, , South Africa
Busan, , South Korea
Cheongju-si, , South Korea
Daegu, , South Korea
Daejeon, , South Korea
Gwangju, , South Korea
Seongnam-si, , South Korea
Seoul, , South Korea
Wŏnju, , South Korea
A Coruña, , Spain
Alicante, , Spain
Almería, , Spain
Ávila, , Spain
Barcelona, , Spain
Burgos, , Spain
Cáceres, , Spain
Elche, , Spain
Granada, , Spain
Lorca, , Spain
Madrid, , Spain
Majadahonda, , Spain
Murcia, , Spain
Olot, , Spain
Orihuela, , Spain
Palma de Mallorca, , Spain
San Juan, , Spain
Sanlúcar de Barrameda, , Spain
Sant Joan Despí, , Spain
Santander, , Spain
Seville, , Spain
Terrassa, , Spain
Torrevieja, , Spain
Valencia, , Spain
Vigo, , Spain
Viladecans, , Spain
Falun, , Sweden
Jönköping, , Sweden
Ljungby, , Sweden
Stockholm, , Sweden
Uppsala, , Sweden
Ankara, , Turkey (Türkiye)
Bursa, , Turkey (Türkiye)
Diyarbakır, , Turkey (Türkiye)
Eskişehir, , Turkey (Türkiye)
Istanbul, , Turkey (Türkiye)
Kahramanmaraş, , Turkey (Türkiye)
Kocaeli, , Turkey (Türkiye)
Konya, , Turkey (Türkiye)
Kırıkkale, , Turkey (Türkiye)
Mersin, , Turkey (Türkiye)
Sivas, , Turkey (Türkiye)
Cherkassy, , Ukraine
Cherkasy, , Ukraine
Dnipro, , Ukraine
Donetsk, , Ukraine
Kharkiv, , Ukraine
Kyiv, , Ukraine
Lutsk, , Ukraine
Lviv, , Ukraine
Odesa, , Ukraine
Poltava, , Ukraine
Sumy, , Ukraine
Vinnitsa, , Ukraine
Vinnytsia, , Ukraine
Zaporizhzhia, , Ukraine
Zaporizhzhya, , Ukraine
Zhytomyr, , Ukraine
Aberdeen, , United Kingdom
Airdrie, , United Kingdom
Birmingham, , United Kingdom
Chesterfield, , United Kingdom
Chichester, , United Kingdom
Clydebank, , United Kingdom
Cottingham, , United Kingdom
Dudley, , United Kingdom
Dundee, , United Kingdom
East Kilbride, , United Kingdom
Exeter, , United Kingdom
Inverness, , United Kingdom
Manchester, , United Kingdom
Metropolitan Borough of Wirral, , United Kingdom
TA1 5DA, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sharma A, Caldeira D, Razaghizad A, Pinto FJ, van Veldhuisen DJ, Mehra MR, Lam CSP, Cleland J, Anker SD, Greenberg B, Ferreira JP, Zannad F. Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF. BMJ Open. 2023 Aug 11;13(8):e068865. doi: 10.1136/bmjopen-2022-068865.
Ferreira JP, Cleland JG, Lam CSP, Anker SD, Mehra MR, van Veldhuisen DJ, Byra WM, La Police DA, Pitt B, Greenberg B, Zannad F. Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE. Clin Res Cardiol. 2021 Oct;110(10):1554-1563. doi: 10.1007/s00392-021-01830-1. Epub 2021 Mar 8.
Ferreira JP, Cleland JGF, Lam CSP, van Veldhuisen DJ, Byra WM, La Police DA, Anker SD, Mehra MR, Leroy C, Eschwege V, Toussaint-Hacquard M, Rossignol P, Greenberg B, Zannad F. Impact of Geographic Region on the COMMANDER-HF Trial. JACC Heart Fail. 2021 Mar;9(3):201-211. doi: 10.1016/j.jchf.2020.11.007. Epub 2021 Feb 3.
Cunningham JW, Ferreira JP, Deng H, Anker SD, Byra WM, Cleland JGF, Gheorghiade M, Lam CSP, La Police D, Mehra MR, Neaton JD, Spiro TE, van Veldhuisen DJ, Greenberg B, Zannad F. Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF. JACC Heart Fail. 2020 May;8(5):359-368. doi: 10.1016/j.jchf.2019.12.009. Epub 2020 Mar 11.
Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF, Lam CSP, van Veldhuisen DJ, Byra WM, Spiro TE, Deng H, Zannad F, Greenberg B. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. Eur Heart J. 2019 Nov 21;40(44):3593-3602. doi: 10.1093/eurheartj/ehz427.
Greenberg B, Neaton JD, Anker SD, Byra WM, Cleland JGF, Deng H, Fu M, La Police DA, Lam CSP, Mehra MR, Nessel CC, Spiro TE, van Veldhuisen DJ, Vanden Boom CM, Zannad F. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. JAMA Cardiol. 2019 Jun 1;4(6):515-523. doi: 10.1001/jamacardio.2019.1049.
Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B; COMMANDER HF Investigators. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi: 10.1056/NEJMoa1808848. Epub 2018 Aug 27.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RIVAROXHFA3001
Identifier Type: OTHER
Identifier Source: secondary_id
2013-000046-19
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CR101940
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.